U.S. Securities and Exchange Commissionregulator
DevelopingETF

Canary Capital files third amendment to staked Injective ETF registration with the SEC

CoinGape reports Canary Capital filed Amendment No. 3 for a staked Injective ETF on Form S-1, seeking a Cboe BZX listing under INJS and staking at least 90% of tokens.

Why it matters

The amendment would add a staking-yield component to a spot crypto ETF, with the reported 90% staking floor representing a change from full staking in earlier filings, and the index and custodian arrangements would set how the fund is priced and held. Only one outlet has reported the filing, so any price movement attributed to it is a single-source account, and no approval decision has been announced.

Where the sources disagree

Amount of INJ the fund would stake

up more than 6%

CoinGape

up 5% to $8.6

CoinGape

CoinGape says the issuer now plans to stake at least 90% of INJ, describing earlier filings as staking all of it, and provides no source reconciling the two.

Key facts

Canary Capital submitted Amendment No. 3 to its Form S-1 for the Canary Staked Injective ETF with the U.S. Securities and Exchange Commission.

Reported by CoinGape

The issuer seeks to list the spot exchange-traded fund on Cboe BZX under the ticker INJS.

Reported by CoinGape

Canary says it expects to stake at least 90% of INJ, compared with all INJ in previous filings.

90 %Reported by CoinGape

The fund is designed to track Injective price performance measured by the CoinDesk Injective Benchmark Rate 60m NY Rate index.

Reported by CoinGape

Canary Capital amended agreements covering price index providers, custodians, and transfer and marketing agents.

Reported by CoinGape

U.S. Bank NA is named in connection with the Canary Staked Injective ETF in a role the source's visible text does not specify.

Reported by CoinGape

CoinGape reported that INJ price jumped more than 6%.

6 %Disputed figureReported by CoinGape

CoinGape reported that INJ rebounded 5% to $8.6 over the last 24 hours, and that futures open interest climbed nearly 11.30% in 24 hours.

8.6 USDDisputed figureReported by CoinGape

What happened

CoinGape reports that Canary Capital submitted Amendment No. 3 to its Form S-1 for the Canary Staked Injective ETF with the U.S. Securities and Exchange Commission. According to that outlet, the amended prospectus covers regulated exposure to spot INJ and to staking rewards, and the issuer is seeking a Cboe BZX listing under the ticker INJS. CoinGape says the issuer now expects to stake at least 90% of INJ held, where earlier filings described staking all of it, and that Canary also amended agreements covering price index providers, custodians, and transfer and marketing agents. The fund is meant to track Injective performance as measured by the CoinDesk Injective Benchmark Rate 60m NY Rate index, and the article names U.S. Bank NA in a role the text it provided does not fully describe. CoinGape also reports that INJ rose more than 6% and that futures open interest climbed nearly 11.30% over 24 hours, describing the token separately as rebounding 5% to $8.6. Nothing in the filing or its approval is confirmed beyond that single report, and the source gives no date for a SEC decision.

How the story developed

  1. First report

    First report by CoinGape

    Canary Capital Amends Its Staked Injective ETF with US SEC, Will INJ Price Rally?

    CoinGape

  2. Update

    Canary Capital files Amendment No. 3 on its staked Injective ETF Form S-1

    The amendment changes the prospectus to offer regulated exposure to spot INJ and staking rewards, adds a 90% staking expectation, and revises agreements with index providers, custodians, and transfer and marketing agents.

    CoinGape

  3. Official statement

    CoinGape reports a Cboe BZX listing sought under the ticker INJS

    The filing targets the CoinDesk Injective Benchmark Rate 60m NY Rate index as the benchmark and names U.S. Bank NA.

    CoinGape

Affected entities

Original sources

PublisherReportRolePublished
CoinGape
Crypto media
Canary Capital Amends Its Staked Injective ETF with US SEC, Will INJ Price Rally?Original